Protecting the nation's health: ensuring a stable supply of influenza vaccine.

The looming threat of an influenza pandemic concerns government officials worldwide as they attempt to address shortages and flaws in the vaccination system. Currently, only two vaccine manufacturers are licensed for U.S. production. This fact, combined with the complexity of production, has resulted in a supply that can be easily interrupted. Policymakers are considering various options to spur research and development, stabilize the supply of vaccines, and improve their prioritization and distribution.